Similarly, the new company that will be spun out of the firm before it's sold, to be known as Seragon Pharmaceuticals Inc., encloses the acronym for "selective estrogen receptor antagonist," characterizing the breast-cancer program with which J&J leaves the company...The spinout is being done before the buyout "for purely corporate-law and tax reasons," he said, adding that J&J was "interested in the breast cancer program, but we and they both agreed that it's tough to pay a lot of money right now

Breast Cancer Recurrence not PAR for Course Researchers from the University of Pennsylvania have identified a protein that plays a role in breast cancer recurrence

to treat advanced non-small-cell lung cancer (NSCLC) as a single agent or in combination with cisplatin, and approved in the European Union to treat NSCLC and advanced or metastatic breast cancer

pexastimogene devacirepvec Hepatocellular carcinoma Fully enrolled the Phase III trial 5/24/13 Medimmune Inc. (Gaithersburg, Md.; unit of Astrazeneca plc) Moxetum-omab pasudotox CD22 immunotoxin made of an anti-CD22 antibody fused to a toxin Hairy-cell leukemia Started the first patient in its Phase III trial 5/17/13 Merrimack Pharmaceuticals Inc. (Cambridge, Mass.) MM-121 A signaling inhibitor targeting ErbB3 Locally advanced or metastatic estrogen receptor-positive or HER2-negative breast

personalized cancer vaccine Advanced ovarian cancer Interim Phase II data showed a positive tumor immune response as measured by enzyme-linked immunospot analysis in 71% of patients 5/16/13 Gtx Inc. (Memphis, Tenn.) Gtx-024 A selective androgen receptor modulator Metastatic breast cancer Started a Phase II study 5/1/13 Izun Pharmaceuticals Corp. (New York) IZN-6N4 Oral rinse Oral mucositis in head and neck cancer Expanded its ongoing Phase II trial to two additional centers, Memorial Sloan

in a $2.9 billion cash and stock deal that brought rights to Abraxis' nanoparticle albumin bound-based drug pipeline, including star cancer drug Abraxane (nap-paclitaxel), approved by the FDA in 2005 for metastatic breast cancer. (See BioWorld Today, July 1, 2010.) Abraxane also had been given the nod for marketing in China, so Celgene "gained about 40 or 50 employees who were already very well integrated in China at a variety of levels," Zeldis said

Galectin Therapeutics Inc., of Norcross, Ga., said preclinical studies have shown that combining the galectin inhibitor GR-MD-02 with monoclonal antibodies that function as immune checkpoint blockade inhibitors enhance shrinkage of prostate and breast cancer tumors...The addition of GR-MD-02, a drug that inhibits galectin proteins, was found to increase tumor shrinkage and enhance survival in immune competent mice with prostate and breast cancers when combined with one of the immune checkpoint

The most interesting of its pipeline is OBI-822/821, a cancer vaccine for metastatic breast cancer...Its products include Lipo-Dox – liposome-encapsulated doxorubicin – for ovarian and breast cancer, and ProFlow, an improved Prostaglandin EI emulsion working as an arterial vasodilator for the treatment of peripheral arterial disease and diabetic neuropathy

Debiopharm Group, of Lausanne, Switzerland, said it treated the first patients in a Phase I study of Debio 1143, a small-molecule neutralizing inhibitor of apoptosis protein, combined with carboplatin and paclitaxel in patients with squamous non-small-cell lung cancer, platinum-refractory ovarian cancer and basal-like/claudin low-triple-negative breast cancer

The study involved 332 patients evaluated in the company's two Phase III trials designed to compare Lymposeek and VBD in patients with breast cancer and melanoma

In December 2012, the company began its BATON-BC Phase II trial of tivozanib in patients with triple negative breast cancer...The randomized, double-blind, multicenter Phase II trial will assess efficacy of tivozanib in combination with paclitaxel compared to placebo with paclitaxel for patients with locally recurrent or metastatic triple-negative breast cancer who have received no previous systemic therapies

The randomized, double-blind, multicenter Phase II trial will assess efficacy of tivozanib in combination with paclitaxel compared to placebo with paclitaxel for patients with locally recurrent or metastatic triple negative breast cancer who have received no previous systemic therapies

Puma Biotechnology Inc., of Los Angeles, began a Phase III trial of PB272 (neratinib) for HER2-positive metastatic breast cancer patients who have failed two or more previous treatments...Participants with third-line HER2-positive metastatic breast cancer will receive PB272 Xeloda or Tykerb plus Xeloda

EntreMed completed Phase I trials of ENMD-2076 in solid tumors, leukemia and multiple myeloma, has an ongoing Phase II study in ovarian cancer and is enrolling additional Phase II studies in triple-negative breast cancer and advanced/soft-tissue sarcoma...As part of its development strategy to use its China resources, in January EntreMed submitted a new drug clinical trial application with the Chinese Food and Drug Administration (CFDA) for ENMD-2076 in triple-negative breast cancer

The most interesting of its pipeline is OBI-822/821 , a cancer vaccine for metastatic breast cancer...Its products include Lipo-Dox – liposome-encapsulated doxorubicin – for ovarian and breast cancer, and ProFlow, an improved Prostaglandin EI emulsion working as an arterial vasodilator for the treatment of peripheral arterial disease and diabetic neuropathy

Based on the findings, the company plans to begin a Phase III trial in gBRCA breast cancer in the fourth quarter...That trial will be powered to show a six-week difference compared to active control in progression-free survival, and will begin in the fourth quarter, enrolling 400 BRCA-mutant breast cancer patients

Sunshine Biopharma Inc., of Montreal, completed an investigational new drug-enabling study of Adva-27a, for breast cancer, finding it effective at killing pancreatic cancer cells in vitro...The company also has data showing that Adva-27a can kill other aggressive and multidrug-resistant cells including breast cancer, small-cell lung cancer and uterine sarcoma

BGB324 rests on research carried out at Bergen University in Norway highlighting an inverse relationship between levels of AXL kinase expression and survival in breast cancer

For example, in breast cancer a large number of patients have radiotherapy first," Levy noted